RxDoctor Payments Data

Joe Aoun

Interventional Cardiology · Houston, TXNPI 1023460276

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,692 of the $19,026 with a category attached, or 72.0%. 28 manufacturers reported payments, led by Medtronic at 33.5% of the total.

$19,026in general payments, 2019–2025

Across 355 payments — averaging $53.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Abbott$6K
  • Boston Scientific$1K
  • Abiomed$1K
  • Edwards Lifesciences$800
  • Philips North America LLC$608
  • plus $3K from 22 others
$139,064in research payments, 2019–2025

Across 5 payments — averaging $27,813 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • W. L. Gore & Associates, Inc.$139K

What the payments were for

  • Travel & lodging$4,95526%
  • Food & beverage$13,69272%
  • Education$3792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,026 in reported general payments places this provider in the 70th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas →

Medicare billing

Part B allowed, 2024
$76,889
Medicare patients
175
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate60$671
Atorvastatin Calcium19$349

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →